Compare · MO vs ONCR
MO vs ONCR
Side-by-side comparison of Altria Group Inc. (MO) and Oncorus Inc. (ONCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MO and ONCR operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- MO is the larger of the two at $113.66B, about 1380.5x ONCR ($82.3M).
- MO has hit the wire 2 times in the past 4 weeks while ONCR has been quiet.
- MO has more recent analyst coverage (21 ratings vs 0 for ONCR).
- Company
- Altria Group Inc.
- Oncorus Inc.
- Price
- $68.08-0.56%
- $0.12-10.15%
- Market cap
- $113.66B
- $82.3M
- 1M return
- -6.62%
- -
- 1Y return
- +2.47%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 2
- 0
- Recent ratings
- 21
- 0
Altria Group Inc.
Altria Group, Inc., through its subsidiaries, manufactures and sells cigarettes, oral tobacco products, and wine in the United States. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. The company also produces and sells varietal and blended table wines, and sparkling wines under the Chateau Ste. Michelle and 14 Hands names; and imports and markets Antinori, Torres, and Villa Maria Estate wines, as well as Champagne Nicolas Feuillatte in the United States. In addition, it provides finance leasing services primarily in transportation, power generation, real estate, and manufacturing equipment industries. The company sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.
Oncorus Inc.
Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Latest MO
- Altria Announces Arrangement with Philip Morris International to Enhance Operational Efficiency
- Philip Morris International Announces Contract Manufacturing Collaboration with Altria
- SEC Form 10-Q filed by Altria Group Inc.
- Altria Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Altria Reports 2026 Second-Quarter and First-Half Results; Narrows 2026 Full-Year Earnings Guidance
- Cadiz Inc. Announces CFO Succession
- BTIG Research initiated coverage on Altria
- Altria to Host Webcast of 2026 Second-Quarter and First-Half Results
- UBS reiterated coverage on Altria with a new price target
- SEC Form 11-K filed by Altria Group Inc.
Latest ONCR
- SEC Form DEFA14A filed by Oncorus Inc.
- SEC Form 15-12G filed by Oncorus Inc.
- SEC Form DEFA14A filed by Oncorus Inc.
- Oncorus Inc. filed SEC Form 8-K: Leadership Update, Other Events, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders
- SEC Form S-8 POS filed by Oncorus Inc.
- SEC Form S-8 POS filed by Oncorus Inc.
- SEC Form S-8 POS filed by Oncorus Inc.
- SEC Form S-8 POS filed by Oncorus Inc.
- SEC Form RW filed by Oncorus Inc.
- Oncorus Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Leadership Update